Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02606136 · ClinicalTrials.gov registry record · Phase 2
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
A Phase 2 study, sponsored by Kyntra Bio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT02606136 is a Phase 2 study that was terminated before completion, run by Kyntra Bio. The registered enrollment target is 21 participants.
The verdict
NCT02606136, a Phase 2 study, was terminated before completion, sponsored by Kyntra Bio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a Phase 2, open-label, single arm trial of pamrevlumab (FG-3019) to estimate pamrevlumab's safety and efficacy in non-ambulatory participants with DMD.
Interventions
- DRUG Pamrevlumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-01-04 |
| Est. Completion | 2023-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02606136
The ClinicalTrials.gov registry entry for NCT02606136 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pamrevlumab is the first listed.
NCT02606136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02606136 about?
NCT02606136 is a clinical study titled "Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)". This is a Phase 2, open-label, single arm trial of pamrevlumab (FG-3019) to estimate pamrevlumab's safety and efficacy in non-ambulatory participants with DMD.
What is the current status of trial NCT02606136?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2016-01-04. Estimated completion is 2023-08-09.
What interventions are being tested in trial NCT02606136?
The interventions under investigation include: Pamrevlumab (DRUG).
Who is sponsoring clinical trial NCT02606136?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.